Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study

Míreanna comhchosúla

• Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
  de réir: Rongce Zhao, et al.
  Foilsithe / Cruthaithe: (2024-05-01)
• The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study
  de réir: Yingxiao Cai, et al.
  Foilsithe / Cruthaithe: (2025-02-01)
• Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma
  de réir: Zhanqi Wei, et al.
  Foilsithe / Cruthaithe: (2023-08-01)
• Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
  de réir: Xiao Y, et al.
  Foilsithe / Cruthaithe: (2024-07-01)
• Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
  de réir: Xiao Y, et al.
  Foilsithe / Cruthaithe: (2023-11-01)